Where does HDL Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), HDL Therapeutics, Inc. ranks #47,351 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does HDL Therapeutics, Inc. hold?

HDL Therapeutics, Inc. holds 5 US utility patents granted between 2020 and 2024, spanning 4 technology areas.

What is HDL Therapeutics, Inc.'s Innovation Score?

HDL Therapeutics, Inc. has an Innovation Score of 27.7 out of 100 (24th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is HDL Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for HDL Therapeutics, Inc..

What does claim depth mean for HDL Therapeutics, Inc.'s patents?

HDL Therapeutics, Inc.'s patents average 16.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the HDL Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

HDL Therapeutics, Inc.

Q: What technology areas does HDL Therapeutics, Inc. focus on?

HDL Therapeutics, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 5 patents. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, HDL ranks #47,351 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.

#47,351
of 49,997 US assignees by volume: 24th percentile
by Innovation Score (27.7/100): 16.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R47351 · US Corporation #47,351 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
BOTTOM-DECILE #47,351/49,997
PHOTO-FINISH Haventec PTY
CPC-NARROW A61K · 4 areas
INNOV-THIN 27.7/100
CLAIMS-RICH 16.6 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2024 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Haventec PTY Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
HDL Therapeutics · this assignee

28
3D Lighting… · lowest

7

What this shows HDL's Innovation Score is 27.7/100 (24th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where HDL's grants concentrate

HDL Therapeutics, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2020. By volume, HDL sits between Haventec PTY Ltd and Healbe Corporation.

HDL's three-year grant acceleration

HDL Therapeutics, Inc. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Haventec PTY

5
Hayabusa Fightwear

5
HCD Agency

5
HDI Railing Syste…

5
Hdpe Solutions

5
HDR

5
Headwaters Heavy…

5
Healbe

5
HDL Therapeutics ◀

5

What this shows HDL holds 5 patents at rank #47,323, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near HDL

By rank, the assignees closest to #47,323 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in HDL's primary technology class.

HDL's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 24th percentile higher than 24% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

HDL Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	20.0%
2021	2	40.0%
2022	1	20.0%
2024	1	20.0%

Which technologies does HDL Therapeutics, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

B01D - Separation 2

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#47,351

of 49,997 tracked assignees

Innovation Score

27.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

HDL Therapeutics, Inc.'s patent record in context - here's where to go next.

HDL Therapeutics, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #47,351 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare HDL Therapeutics, Inc. against Haventec PTY Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.